Skip to main content
Publications
Dong OM, Roberts MC, Wu RR, Voils CI, Sperber N, Gavin KL, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Chapman JG, Voora D. Evaluation of the veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program at initial test sites. Pharmacogenomics. 2021 Nov 1;22(17):1121-33. doi: 10.2217/pgs-2021-0089
Dong OM, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Meyer LJ, Icardi M, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Jacobitz R, Rozelle S, Chapman JG, Voora D. Institutional profile: veterans affairs pharmacogenomic testing for veterans (PHASER) program. Pharmacogenomics. 2021 Jan 6;22(3):2020-0173. doi: 10.2217/pgs-2020-0173
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassils C, Nyirady J, Lebwohl M. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236
Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassils C, Nelson LM, McLeod LD, Mordin M, Gottlieb A, Elewski B, Lebwohl M. Psychometric validation of the psoriasis symptom diary using phase III study data from patients with chronic plaque psoriasis. Int J Dermatol. 2016 Mar;55(3):e147-55. doi: 10.1111/ijd.13117